Glycopyrrolate in comparison to hyoscine hydrobromide and placebo in the treatment of hypersalivation induced by clozapine (GOTHIC1): study protocol for a randomised controlled feasibility study

Inti Qurashi, Simon Chu, Nusrat Husain, Richard J Drake, Imran Chaudhry, J F W Deakin, Inti Qurashi, Simon Chu, Nusrat Husain, Richard J Drake, Imran Chaudhry, J F W Deakin

Abstract

Background: Clozapine is the only medication licensed for the treatment of resistant schizophrenia in the UK. Although efficacious, a common and unpopular side effect of clozapine treatment is clozapine-induced hypersalivation (CIH), which can contribute to non-adherence. The standard treatment for CIH in the UK is hyoscine hydrobromide but this may aggravate cognitive deficits in patients with schizophrenia while glycopyrrolate may be an effective alternative with a more tolerable side effect profile. There is currently no convincing evidence for hyoscine, or any other medication, as an effective treatment for CIH.

Methods/design: This is a multicentre randomised, double-blind, placebo-controlled feasibility study of glycopyrronium bromide (glycopyrrolate) and hyoscine hydrobromide (hyoscine) in patients with clozapine-induced hypersalivation. We aim to recruit 42 patients who have been prescribed clozapine and are experiencing hypersalivation, and randomise them to one of three study arms (either hyoscine, glycopyrrolate or placebo). The primary outcome measures will be the participant recruitment and attrition rates, and the secondary outcome will be the metrics of the daytime hypersalivation measure. After a 1-week washout period (discontinuing CIH medication, if any), there will be a 4-week treatment period where participants will be titrated up to the maximum tolerated dose of hyoscine, glycopyrrolate or placebo. Measurements of daytime salivation, nocturnal salivation, cognition and side effects will be taken during home visits in week 2 and week 5. Information on salivation and side effects will also be taken through telephone calls in week 3 and week 4. To gather information on the experience of study participants, exit interviews will also be requested with all participants who drop out of the study and a sample of participants who complete the study.

Discussion: There is currently no convincing evidence for hyoscine, or any other medication, as an effective treatment for CIH. There is promising evidence that glycopyrrolate may be more successful in the treatment of CIH causing fewer cognitive side effects. We propose to conduct a randomised placebo-controlled feasibility study of glycopyrrolate and hyoscine in the treatment of clozapine-induced hypersalivation to inform the design of a future efficacy trial.

Trial registration: Clinicaltrials.gov NCT02613494 , 23 November 2015.

Keywords: Adult; Clozapine; Feasibility; Glycopyrrolate; Hyoscine; Randomised trial; Sialorrhea.

Figures

Fig. 1
Fig. 1
Study flow chart for GOTHIC1

References

    1. Waserman J, Criollo M. Subjective experiences of clozapine treatment by patients with chronic schizophrenia. Psychiatr Serv. 2000;51(5):666–8. doi: 10.1176/appi.ps.51.5.666.
    1. Safferman A, Lieberman JA, Kane JM. Update on the clinical efficacy and side-effects of clozapine. Schizophr Bull. 1991;17(2):247–61. doi: 10.1093/schbul/17.2.247.
    1. Brodkin ES, Pelton GH, Price LH. Treatment of clozapine-induced parotid gland swelling. Am J Psychiatry. 1996;153(3):445.
    1. Hinkes R, Quesada T, Currier MB. Aspiration pneumonia possibly secondary to clozapine-induced sialorrhea. J Clin Psychopharmacol. 1996;16(6):462–3. doi: 10.1097/00004714-199612000-00013.
    1. Qurashi I, Stephenson P, Chu S, Duffy C, Husain N, Chaudhry I. An evaluation of subjective experiences, effects and overall satisfaction with clozapine treatment in a UK forensic service. Ther Adv Psychopharmacol. 2015;5(3):146–50. doi: 10.1177/2045125315581996.
    1. Krivoy A, Malka L, Fischel T, Weizman A, Valevski A. Predictors of clozapine discontinuation in patients with schizophrenia. Int Clin Psychopharmacol. 2011;26(6):311–15. doi: 10.1097/YIC.0b013e32834ab34c.
    1. UK Medicines Information for NHS healthcare professionals. ‘Q and A 54.4. Drug-induced hypersalivation – what treatment options are available?’ . Accessed 17 Nov 2016.
    1. Sherman SJ, Atri A, Hasselmo ME, Stern CE, Howard MW. Scopolamine impairs human recognition memory: data and modelling. Behav Neurosci. 2003;117(3):526–39. doi: 10.1037/0735-7044.117.3.526.
    1. Sockalingam S, Shammi C, Remington G. Clozapine-induced hypersalivation: a review of treatment strategies. Can J Psychiatry. 2007;52(6):377–84.
    1. Syed R, Au K, Cahill C, Duggan L, He Y, Udu V, Xia J. Pharmacological interventions for clozapine-induced hypersalivation. Cochrane Database Syst Rev. 2008;3:CD005579.
    1. Reddihough D, Reid S, Plover C. Evaluation of glycopyrrolate in the treatment of chronic drooling. Degener Neurol Neuromuscul Dis. 2011;1:3–7.
    1. Parr JR, Buswell CA, Banerjee KJ, Fairhurst C, Williams J, O’Hare A. Management of drooling: a survey of UK clinicians’ clinical practice. Child Care Health Dev. 2012;38:287–91. doi: 10.1111/j.1365-2214.2011.01213.x.
    1. Mier RJ, Bachrach SJ, Lakin RC, Barker T, Childs J, Moran M. Treatment of sialorrhea with glycopyrrolate: a double-blind, dose-ranging study. Arch Pediatr Adolesc Med. 2000;154(12):1214–8. doi: 10.1001/archpedi.154.12.1214.
    1. Zeller R, Davidson J, Lee H, Cavanaugh P. Safety and efficacy of glycopyrrolate oral solution for management of pathological drooling in paediatric patients with cerebral palsy and other neurological conditions. Ther Clin Risk Manage. 2012;8:25–32. doi: 10.2147/TCRM.S27362.
    1. Arbouw ME, Movig KL, Koopmann M, Poels PJ, Guchelaar HJ, Egberts TC, Nef C, van Vugt JP. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology. 2010;74(15):1203–7. doi: 10.1212/WNL.0b013e3181d8c1b7.
    1. Robb AS, Lee RH, Cooper EB, Siedel JV, Nusrat N. Glycopyrrolate for treatment of clozapine-induced sialorrhea in three adolescents. J Child Adolesc Psychopharmacol. 2008;18(1):99–107. doi: 10.1089/cap.2007.0037.
    1. Liang CS, Ho PS, Shen LJ, Lee WK, Yang FW, Chiang KT. Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study. Schizophr Res. 2010;119(1-3):138–44. doi: 10.1016/j.schres.2010.02.1060.
    1. British Medical Association and the Royal Pharmaceutical Society . British National Formulary (62) London: Pharmaceutical Press; 2011.
    1. Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry. 12. London: Wiley-Blackwell; 2015.
    1. Thomas-Stonell N, Greenberg J. Three treatment approaches and clinical factors in the reduction of drooling. Dysphagia. 1988;3(2):73–8. doi: 10.1007/BF02412423.
    1. Evatt ML. Oral glycopyrrolate for the treatment of chronic severe drooling caused by neurological disorders in children. Neuropsychiatr Dis Treat. 2011;7:543–7. doi: 10.2147/NDT.S14028.
    1. Spivak B, Adlersberg S, Rosen L, Gonen N, Mester R, Weizman A. Trihexyphenidyl treatment of clozapine-induced hypersalivation. Int Clin Psychopharmacol. 1997;12:213–5. doi: 10.1097/00004850-199707000-00005.
    1. Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68:283–97. doi: 10.1016/j.schres.2003.09.011.
    1. Day JC, Wood G, Dewey M, Bentall RP. A self-rating scale for measuring neuroleptic side-effects: Validation in a group of schizophrenic patients. Br J Psychiatry. 1995;166:650–53. doi: 10.1192/bjp.166.5.650.
    1. Moore CG, Carter RE, Nietert PJ, Stewart PW. Recommendations for planning pilot studies in clinical and translational research. Clin Transl Sci. 2011;4(5):332–7. doi: 10.1111/j.1752-8062.2011.00347.x.
    1. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 2005;4:287–91. doi: 10.1002/pst.185.
    1. Schoenfeld D. Statistical considerations for pilot studies. Int J Radiat Oncol Biol Phys. 1980;6(3):371–74. doi: 10.1016/0360-3016(80)90153-4.
    1. World Health Organization . Handbook for good clinical research practice (GCP): guidance for implementation. Geneva: WHO; 2005.
    1. World Medical Association: Declaration of Helsinki. Ethical principles for medical research involving human subjects. . Accessed 17 Nov 2016.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner